Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?

Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonm...

Full description

Bibliographic Details
Main Authors: Rupam Borgohain, Rukmini Mridula Kandadai, Afshan Jabeen, Meena A. Kannikannan
Format: Article
Language:English
Published: SAGE Publishing 2012-01-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285611423412
id doaj-6b833e27e1a24b8aa4ae72ebdada2e6a
record_format Article
spelling doaj-6b833e27e1a24b8aa4ae72ebdada2e6a2020-11-25T02:59:17ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642012-01-01510.1177/1756285611423412Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?Rupam BorgohainRukmini Mridula KandadaiAfshan JabeenMeena A. KannikannanNonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonmotor symptoms is not well known. Compared with pharmacological therapy, bilateral subthalamic nucleus (STN)-DBS or globus pallidum interna (GPi)-DBS has significant beneficial effects on pain, sleep, gastrointestinal and urological symptoms. STN-DBS is associated with a mild worsening in verbal fluency while GPi-DBS has no effect on cognition. STN-DBS may improve cardiovascular autonomic disturbances by reducing the dose of dopaminergic drugs. Because the motor effects of STN-DBS and GPi-DBS appear to be similar, nonmotor symptoms may determine the target choice in surgery of future patients.https://doi.org/10.1177/1756285611423412
collection DOAJ
language English
format Article
sources DOAJ
author Rupam Borgohain
Rukmini Mridula Kandadai
Afshan Jabeen
Meena A. Kannikannan
spellingShingle Rupam Borgohain
Rukmini Mridula Kandadai
Afshan Jabeen
Meena A. Kannikannan
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
Therapeutic Advances in Neurological Disorders
author_facet Rupam Borgohain
Rukmini Mridula Kandadai
Afshan Jabeen
Meena A. Kannikannan
author_sort Rupam Borgohain
title Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
title_short Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
title_full Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
title_fullStr Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
title_full_unstemmed Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
title_sort nonmotor outcomes in parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
publisher SAGE Publishing
series Therapeutic Advances in Neurological Disorders
issn 1756-2856
1756-2864
publishDate 2012-01-01
description Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonmotor symptoms is not well known. Compared with pharmacological therapy, bilateral subthalamic nucleus (STN)-DBS or globus pallidum interna (GPi)-DBS has significant beneficial effects on pain, sleep, gastrointestinal and urological symptoms. STN-DBS is associated with a mild worsening in verbal fluency while GPi-DBS has no effect on cognition. STN-DBS may improve cardiovascular autonomic disturbances by reducing the dose of dopaminergic drugs. Because the motor effects of STN-DBS and GPi-DBS appear to be similar, nonmotor symptoms may determine the target choice in surgery of future patients.
url https://doi.org/10.1177/1756285611423412
work_keys_str_mv AT rupamborgohain nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy
AT rukminimridulakandadai nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy
AT afshanjabeen nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy
AT meenaakannikannan nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy
_version_ 1724703274704044032